Form 4: Odyssey Health, Inc. Divests Entire Stake in Oragenics Inc.

Odyssey Health, Inc., a 10% owner and director of Oragenics Inc. (OGEN), has reported the complete sale of its common stock holdings in the company across two transactions in June 2025.

Summary

• Odyssey Health, Inc., identified as a Director and 10% Owner of Oragenics Inc. (OGEN), filed a Form 4 detailing recent stock transactions.
• On June 17, 2025, Odyssey Health, Inc. sold 2,000 shares of OGEN common stock at a price of $4.46 per share.
• Following this transaction, Odyssey Health, Inc. beneficially owned 5,044 shares of OGEN common stock directly.
• On June 18, 2025, Odyssey Health, Inc. sold its remaining 5,044 shares of OGEN common stock at a price of $4.26 per share.
• After these two transactions, Odyssey Health, Inc. holds 0 shares of OGEN common stock directly, indicating a complete divestment of its position.

Sentiment

Score: 3

Explanation: The complete divestment of shares by a significant insider (10% owner and director) is a strong negative signal, indicating a lack of confidence or a strategic exit. This typically leads to negative market sentiment.

Negatives

• A significant shareholder and director, Odyssey Health, Inc., has completely divested its stake in Oragenics Inc., which can be interpreted as a lack of confidence.
• The sales occurred at prices of $4.46 and $4.26 per share, representing a full exit from the investment.

Future Outlook

NA

Industry Context

This Form 4 filing indicates a significant insider selling event, where a director and major shareholder has fully exited their position. Such divestments by key stakeholders can sometimes signal a lack of confidence in the company's future prospects, potentially impacting investor sentiment within the biotechnology or pharmaceutical industry, where Oragenics Inc. operates.

Stakeholder Impact

• Shareholders may view the complete divestment by a significant insider as a negative signal, potentially leading to decreased investor confidence and downward pressure on the stock price.

Key Dates

Recommendation

Keywords

Oragenics Inc., OGEN, Odyssey Health Inc., Form 4, Insider Selling, Beneficial Ownership, Stock Sale, Director Selling, 10% Owner